Daily Morning Note – 21 November 2020

PHILLIP SUMMARY

Stocks looked set for a cautious start to the week as traders monitored developments on progress toward a vaccine. The pound ticked up. S&P 500 futures opened with little fanfare and Australian shares edged higher in early Monday trading as global equities remain within a whisker of the record high set earlier this month. Vaccinations against Covid-19 in the U.S. will “hopefully” start in less than three weeks, according to the head of the federal government’s program to accelerate a vaccine. Japan is shut for a holiday and Treasuries won’t trade until the London open.

BREAKING NEWS

INVESTORS will have easier access to Hong Kong-listed technology stocks next month, as OCBC works towards the listing of a tech-focused exchange-traded fund on the Singapore Exchange. The Lion-OCBC Securities Hang Seng TECH ETF will track the Hang Seng TECH Index, which is made up of the top 30 technology companies listed in Hong Kong by market capitalisation.

China will show “zero tolerance” for misconduct following a recent string of bond defaults, a meeting of the Financial Stability and Development Committee chaired by Vice-Premier Liu He said. Fraudulent issuance, disclosure of false information, malicious transfer of assets and misappropriation of issuance funds will be strictly investigated, said the meeting, according to an account posted on a government website.

General Electric and a Vietnamese company signed a memorandum of understanding to develop an LNG (liquified natural gas) power plant near Ho Chi Minh City. The signing between GE and EVN Genco3 took place during an event with President Donald Trump’s National Security Adviser Robert O’Brien in Hanoi on Saturday. Mr O’Brien, in Vietnam for a three-day visit which includes meetings with government officials and a speech to international relations students, said the companies will develop a plant that will provide 3,600 megawatts of power.

On Nov 18, Medtecs International Corporation executive director and CEO William Yang Weiyuan acquired one million shares of the listed company for a consideration of S$921,998 at an average price of 92.20 cents per share. According to the filing, Mr Yang was not previously holding Medtecs shares. The share price of Medtecs has soared from 3.7 cents at the end 2019 to 92.00 cents as of Nov 19.

CATALIST-LISTED Jiutian Chemical Group recently became the world’s second-largest dimethylformamide (DMF) producer, after a competitor exited the business. The economics of its chemicals production business have also improved, and the company expects this situation may continue for some time.

Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR

TECHNICAL REPORTS

NetEase Inc

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

NetEase Inc (US: NTES) corrective downside may soon be coming to an end based on the technical and wave analysis.

Sea Limited

Analyst: Chua Wei Ren

Recommended Action: Technical BUY

Sea Limited (US: SE) upside is still on play despite some minor correction since our report dated 28th October 2020. Recent technical indicate a return of the upside once more

>> Read more Technical reports

RESEARCH REPORTS

Singapore REITs Monthly – Looking beyond near-term weakness

Recommendation: OVERWEIGHT (Maintained), Analyst: Natalie Ong

– FTSE S-REIT Index underperformed the STI and Real Estate Developer Index. Hospitality segment was the best performer, up 16.0%, lifted by news of vaccine progress. Industrial segment fared the worst, down 2.2%.

– Sector yield spread of 338bps over the benchmark 10-year SGS (10YSGS) was -0.1SD.

– Remain OVERWEIGHT on SREITs with catalysts expected from acquisitions fuelled by the conducive interest rate environment. Sub-sector preferences are hospitality (upgraded), office and industrial. Top picks are Manulife US REIT (MUST SP, Buy, TP: US$0.92), Frasers Centrepoint Trust (FCT SP, Accumulate, TP: S$2.79) and Ascendas REIT (AREIT SP, BUY, S$3.61).

SG Bonds Weekly – Week 48

Credit Analyst: Timothy Ang

– Activity in the Asia primary debt market was largely muted as the market digests the impact of Trump’s ban on investments in securities related to the Chinese military.

– Newly formed holding company Aviva Singlife Holdings Pte Ltd has priced S$550 million of 10.25-year callable subordinated notes at 3.375 per cent.

– The People’s Republic of China sold its first negative-yielding government bond this week in a three-tranche euro-denominated issuance that that was dominated by yield hungry European investors.

>> Read more research reports

HK Reports – Read up on our Hong Kong reports here

RESEARCH VIDEOS

Webinar Of The Week

Market Outlook: (PSR) StarHub, Banks & REIT Results, Banking Monthly, Credit Commentary, SG Weekly & more

Date: 09 November 2020

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #26 – iX Biopharma Ltd; Initiation

For more videos on Phillip in 3 Mins

Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com